TD Cowen Reaffirms Buy Rating for Zoetis Inc. with $104 Target
TD Cowen maintains its Buy rating on Zoetis Inc., setting a price target of $104, a 44.73% upside from the current price.
Key Points
- On June 30, 2026, TD Cowen reiterated its Buy rating for Zoetis Inc. (NYSE:ZTS) with a price target of $104.
- TD Cowen's $104 price target implies 44.73% upside from Zoetis Inc.'s ($ZTS) current $71.86 share price.
- Zoetis shares traded at $73.25 on Tuesday, with a market cap of about $31.9 billion and a P/E ratio of 12.5.
- Recent insider transactions include Mark Stetter's purchase of 318 shares at $78.71 on June 18, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
TD Cowen reiterated its Buy rating for Zoetis Inc. (NYSE:ZTS) on June 30, 2026, maintaining a price target of $104. Analyst Steve Scala emphasized the firm's positive outlook on Zoetis, a leading player in the animal health industry.
TD Cowen vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Zoetis Inc. Stock Down 7.1%
Shares of NYSE:ZTS traded near $73.25 on Tuesday. Zoetis boasts a market cap of approximately $31.9 billion, with a P/E ratio of 12.5 and a forward P/E of 10.3. The stock's 52-week range is between $72.38 and $161.77, with a 50-day moving average of $90.03 and a 200-day moving average of $118.84. The company maintains a current ratio of 3.15 and a quick ratio of 1.68.
$ZTS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Zoetis reported revenue of $9.53 billion, reflecting a growth rate of 2.9%. The company achieved a net margin of 28.0% and a return on equity of 67.7%. Its EPS stood at $6.10. Investors are looking forward to the next earnings report, scheduled for August 6, 2026.
Dividend
Zoetis offers an annual dividend rate of $2.12, yielding 2.79%. The payout ratio is approximately 33.3%, providing a steady income stream for investors.
Insider Buying and Selling at Zoetis Inc.
Recent insider activity at Zoetis includes Mark Stetter buying 318 shares at an average price of $78.71 on June 18, 2026. Other transactions involved Michael McCallister selling 1,209 shares on June 10, 2026, and Louise Parent's multiple sales on May 20, 2026.
Analysts Set New Price Targets
On June 30, 2026, TD Cowen maintained its Buy rating on Zoetis with a $104 price target. Stifel held its Hold rating with an $85 target on June 26, 2026. Meanwhile, Citigroup reiterated a Buy rating with a $112 target on May 18, 2026. Overall, the consensus recommendation remains a Buy, with a mean target price of $124 among 17 analysts.
About Zoetis Inc.
Zoetis Inc., headquartered in Parsippany, New Jersey, is a leading company in the healthcare sector, specializing in animal health. The firm develops and sells medicines, vaccines, and diagnostic products for various animals, including livestock and pets. With a workforce of around 14,500 employees, Zoetis is committed to innovation in animal health solutions.
Bottom Line
Zoetis Inc. remains a key player in the animal health industry, attracting attention from analysts like TD Cowen. Their reiterated Buy rating and $104 target reflect confidence in Zoetis's growth potential. Investors should note that analyst ratings are forward-looking and subject to change based on market conditions.
Get Zoetis Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZTS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.